CA3105743A1 - Methods to reduce complications of intra-articular steroid - Google Patents
Methods to reduce complications of intra-articular steroid Download PDFInfo
- Publication number
- CA3105743A1 CA3105743A1 CA3105743A CA3105743A CA3105743A1 CA 3105743 A1 CA3105743 A1 CA 3105743A1 CA 3105743 A CA3105743 A CA 3105743A CA 3105743 A CA3105743 A CA 3105743A CA 3105743 A1 CA3105743 A1 CA 3105743A1
- Authority
- CA
- Canada
- Prior art keywords
- weeks
- steroid
- articular
- pharmaceutical composition
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862695763P | 2018-07-09 | 2018-07-09 | |
| US62/695,763 | 2018-07-09 | ||
| US201962839231P | 2019-04-26 | 2019-04-26 | |
| US62/839,231 | 2019-04-26 | ||
| PCT/US2019/040794 WO2020014118A1 (en) | 2018-07-09 | 2019-07-08 | Methods to reduce complications of intra-articular steroid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3105743A1 true CA3105743A1 (en) | 2020-01-16 |
Family
ID=67441711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3105743A Pending CA3105743A1 (en) | 2018-07-09 | 2019-07-08 | Methods to reduce complications of intra-articular steroid |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12083138B2 (https=) |
| EP (1) | EP3820479B1 (https=) |
| JP (1) | JP7463306B2 (https=) |
| KR (2) | KR20210031715A (https=) |
| CN (1) | CN112469420A (https=) |
| AU (1) | AU2019301542B2 (https=) |
| BR (1) | BR112021000316A2 (https=) |
| CA (1) | CA3105743A1 (https=) |
| SG (1) | SG11202100054YA (https=) |
| TW (1) | TWI857961B (https=) |
| WO (1) | WO2020014118A1 (https=) |
| ZA (1) | ZA202100604B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023019192A1 (en) * | 2021-08-11 | 2023-02-16 | Board Of Regents, The University Of Texas System | Dry liposome formulations and related methods thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| DE10255106A1 (de) * | 2002-11-24 | 2004-06-09 | Novosom Ag | Liposomale Glucocorticoide |
| US20130296267A1 (en) * | 2008-01-18 | 2013-11-07 | Horst Kief | Agent for intra-articular injection |
| US8956600B2 (en) | 2009-08-10 | 2015-02-17 | Taiwan Liposome Co. Ltd. | Ophthalmic drug delivery system containing phospholipid and cholesterol |
| UA111162C2 (uk) | 2010-08-04 | 2016-04-11 | Флекшен Терап'Ютікс, Інк. | Ін'єкційна композиція ацетоніду триамцинолону для лікування болю |
| RU2660585C2 (ru) * | 2012-02-10 | 2018-07-06 | Тайвэн Липосом Компани, Лтд. | Фармацевтическая композиция для уменьшения осложнений применения стероидных препаратов при лечении офтальмологических заболеваний |
| SI2854769T1 (sl) * | 2012-07-05 | 2023-09-29 | Taiwan Liposome Company, Ltd. | Postopki za zdravljenje artritisa |
| TWI845973B (zh) | 2015-01-21 | 2024-06-21 | 美商桑紐爾製藥公司 | 醫藥配方 |
-
2019
- 2019-07-08 WO PCT/US2019/040794 patent/WO2020014118A1/en not_active Ceased
- 2019-07-08 AU AU2019301542A patent/AU2019301542B2/en active Active
- 2019-07-08 CN CN201980045714.5A patent/CN112469420A/zh active Pending
- 2019-07-08 EP EP19745471.3A patent/EP3820479B1/en active Active
- 2019-07-08 CA CA3105743A patent/CA3105743A1/en active Pending
- 2019-07-08 SG SG11202100054YA patent/SG11202100054YA/en unknown
- 2019-07-08 JP JP2020573183A patent/JP7463306B2/ja active Active
- 2019-07-08 US US17/252,382 patent/US12083138B2/en active Active
- 2019-07-08 KR KR1020217003687A patent/KR20210031715A/ko not_active Ceased
- 2019-07-08 BR BR112021000316-9A patent/BR112021000316A2/pt unknown
- 2019-07-08 KR KR1020257019987A patent/KR20250093579A/ko active Pending
- 2019-07-09 TW TW108124124A patent/TWI857961B/zh active
-
2021
- 2021-01-27 ZA ZA2021/00604A patent/ZA202100604B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3820479B1 (en) | 2026-03-11 |
| AU2019301542A1 (en) | 2021-02-25 |
| JP2021532074A (ja) | 2021-11-25 |
| TWI857961B (zh) | 2024-10-11 |
| AU2019301542B2 (en) | 2025-04-03 |
| TW202007398A (zh) | 2020-02-16 |
| JP7463306B2 (ja) | 2024-04-08 |
| EP3820479A1 (en) | 2021-05-19 |
| US12083138B2 (en) | 2024-09-10 |
| SG11202100054YA (en) | 2021-02-25 |
| ZA202100604B (en) | 2025-05-28 |
| CN112469420A (zh) | 2021-03-09 |
| BR112021000316A2 (pt) | 2021-04-06 |
| KR20210031715A (ko) | 2021-03-22 |
| WO2020014118A1 (en) | 2020-01-16 |
| KR20250093579A (ko) | 2025-06-24 |
| US20210196733A1 (en) | 2021-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2854769B1 (en) | Methods of treating arthritis | |
| US12208104B2 (en) | Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain | |
| AU2019301542B2 (en) | Methods to reduce complications of intra-articular steroid | |
| RU2806023C2 (ru) | Способы уменьшения осложнений от внутрисуставного стероида | |
| RU2810788C2 (ru) | Фармацевтические композиции, подходящие для суставной доставки, и их применение при лечении суставной боли | |
| US12514820B2 (en) | Pharmaceutical composition of intra-articular corticosteroid for pain control | |
| HK40041258A (en) | Methods to reduce complications of intra-articular steroid | |
| HK40041739A (en) | Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220815 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241024 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20250130 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250130 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250219 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250604 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250604 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250703 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250703 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250714 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20250908 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250908 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260115 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260127 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260421 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260421 |